Compare Heron Therapeutics Inc (HRTX) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kraft Heinz Co — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Kraft Heinz Co trades at $22.51 (market cap $26.06B). The key difference: Kraft Heinz Co is far larger — about 352× Heron Therapeutics Inc's market cap, and Kraft Heinz Co pays a 7.28% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Kraft Heinz Co for 129 Days on average.
| HRTX | KHC | |
|---|---|---|
Market Cap | $74.04M | $26.06B |
Volume | 3,668,095 | 15,326,651 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $27.62 |
52-Week Low | $0.27 | $21.21 |
Typical Hold Time | 35 Days | 129 Days |
Enterprise Value | $180.78M | $42.38B |
Dividend Yield | — | 7.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Kraft Heinz (KHC) trades at $22.48, up 2.04% today, with a bearish technical signal but recent earnings beats. The stock shows a low P/E of 13.04 and P/B of 0.72, yet profitability is weak with a -13.64% net margin. Cash flow improved to $1.46B in 2025, but a $5.85B net loss and high debt of $19.22B pose challenges. News highlights dividend stability and brand revitalization efforts, such as new Philadelphia cream cheese flavors.
Outlook remains cautious; the stock offers value with a dividend yield near 6%, but turnaround success is critical. Risks include sustained volume declines and debt servicing. Analysts are mixed with a $23.78 consensus target, suggesting limited upside. Institutional interest exists, but weak fundamentals warrant careful monitoring for recovery signs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
